Genetron Health Enters into Platform Partnership with World Economic Forum

Rhea-AI Summary

Genetron Holdings Limited (NASDAQ: GTH), a leading precision oncology platform in China, has formed a partnership with the World Economic Forum (WEF) to enhance global health access. Through this collaboration, Genetron will contribute its expertise and technologies to the WEF's Health and Healthcare Platform, focusing on initiatives like the project 'Moving Genomics to the Clinic,' aimed at integrating genetic testing in healthcare practices. The partnership aims to drive impactful advancements in the healthcare sector and aligns with Genetron's mission to foster technological innovation and healthcare development in China.

Positive

• New partnership with WEF to enhance global health access.
• Collaboration aims to promote genetic testing in clinical practice.
• Alignment of Genetron’s goals with WEF’s healthcare initiatives.

Negative

• None.

BEIJING, July 02, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a new partnership with the World Economic Forum (WEF), under its Health and Healthcare Platform.

Genetron Health, as a platform partner, will contribute its research insights, technologies, and industry experience to future projects with the WEF through the “Platform of Shaping the Future of Health and Healthcare”. Being one of WEF’s industry engagement platforms, its goal is to ensure worldwide equal access to the highest standards of health and healthcare, by helping stakeholders keep populations healthy and deliver the best care. The platform also consists of subject matter experts and fellows that include policymakers, academics, and international organizations. Together, Genetron Health and the WEF will work to drive more impact and action in the global healthcare industry.

Genya Dana, head of the WEF’s healthcare platform, said during an onboarding conference call on Wednesday: “We are very pleased to have a leading precision medicine company, Genetron Health, on board. The Company has been working with us for some time already, and we look forward to exploring more areas of collaboration.”

Genetron Health is currently involved in the WEF project, “Moving Genomics to the Clinic”, which promotes the use of genetic testing in routine clinical practices by proving its utility and efficacy. On a broader level, the project serves to help the world better prepare for and respond to epidemics.

“As an international organization that is well-recognized for its efforts to promote public-private cooperation, the WEF has made a strong impact on the world’s healthcare sector. We are pleased to announce this new partnership with the WEF,” said Genetron Health Co-founder and CEO Sizhen Wang.

Through participating in the WEF’s past dialogues and research projects, Genetron Health has found that the WEF’s Health and Healthcare Platform shares many of its values and goals. “There are two missions that Genetron Health focuses on. The first is to drive technological innovation to solve the problems that we could not solve in the past. The second is to be a leading industry participant and help push forward China’s healthcare development. We believe that there are many opportunities that we can work together on to achieve these missions,” said Wang.

In June of last year, Genetron Health was named by WEF as one of its “Technology Pioneers 2020”. In April of this year, Sizhen Wang, Co-founder and CEO of Genetron Health, published a bylined article on WEF’s platform to advocate the use of liquid biopsy technology in early cancer screening and diagnosis.

About Genetron Holdings Limited

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.

Media Relations Contact
Yanrong Zhao
Email: yanrong.zhao@genetronhealth.com

Investor Relations Contact
Hoki Luk
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 891-9255

FAQ

What is the significance of Genetron's partnership with the World Economic Forum (WEF)?

The partnership allows Genetron to contribute insights and technology to improve global health access, enhancing its engagement in precision oncology.

What project is Genetron currently involved in with the WEF?

Genetron is participating in the WEF project 'Moving Genomics to the Clinic,' which focuses on integrating genetic testing into routine clinical practices.

How does the partnership with WEF impact Genetron Holdings (GTH)?

The partnership may enhance Genetron's reputation and influence in the healthcare industry, potentially leading to increased collaboration opportunities.

What are Genetron's primary missions as mentioned in the press release?

Genetron aims to drive technological innovation in healthcare and support the development of China's healthcare system.